Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Kamada Said to Seek as Much as $50 Million in Nasdaq Listing

Kamada Ltd., the Israeli maker of treatments for hereditary lung diseases, hired Morgan Stanley and Jefferies Group Inc. to arrange the sale of as much as $50 million in stock in the U.S., according to a person familiar with the plans.

A prospectus will be filed with the Securities and Exchange Commission soon, and the proceeds will be used to develop the business, said the person, who asked not to be named because they weren’t authorized to speak publicly about the sale. The shares will be traded on Nasdaq, the person said. Chief Financial Officer Gil Efron declined to comment when contacted by telephone. A spokeswoman for Jefferies in London declined to immediately comment. A spokesman for Morgan Stanley in London declined to comment.

Kamada said in December that it was examining a sale of shares in the U.S., adding that no decision had been made on the size and timing of the offering. The stock gained 62 percent last year and 4 percent this year, giving the Nes Ziona-based company a market value of almost 990 million shekels ($262 million).

“The main idea for Kamada at this point is to get feedback from a sophisticated market,” said Nir Zonenberg, head of research at Meitav Investment House, which holds a 4.99 percent stake in Kamada. “Kamada probably thinks the American market is better equipped to grasp the significance of its upcoming results.”

Distribution Deal

The company announced on Aug. 5 an agreement with Chiesi Farmaceutici SpA for the exclusive distribution of the inhaled version of its medicine for a genetic condition called Alpha-1 Antitrypsin deficiency that can lead to liver and lung damage. The inhaled version is in later stages of human testing in Europe and results are expected this year.

Kamada said the Chiesi agreement could bring in $60 million if regulatory conditions and sales targets are met and estimates sales potential of “hundreds of millions of dollars.” The company already sells an intravenous version of the AAT treatment with Baxter International Inc.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.